Enter your login e-mail to the account
Search
Search parameters
Search results
- Overview of resulsts in selected phramacoeconomic study of betablocker carvedilol
Mgr. Matúš Džupon, doc. PhDr. Róbert Babeľa, PhD., MBA, doc. PharmDr. Tomáš Tesař, PhD., MBA
(6/2009, Pharmacoeconomics ) - Novinky vo farmakoterapii: Kategorizácia od 1. júla 2009
Ing. Mgr. Dagmar Hroncová
(6/2009, Information & comments ) - Overview of results in selected pharmacoeconomic studies with valsartan
PharmDr. Tomáš Tesař, PhD., MBA, Mgr. Matúš Džupon, doc. PhDr. Róbert Babeľa, PhD., MBA
(11/2009, Pharmacoeconomics ) - Overview of results in selected in pharmacoeconomic study of ACEi perindopril
PharmDr. Tomáš Tesař, PhD., MBA, Mgr. Matúš Džupon, doc. PhDr. Róbert Babeľa, PhD., MBA
(3/2009, Pharmacoeconomics ) - ECONOMIC EVALUATION IN HEALTHCARE SYSTEM
doc. PhDr. Róbert Babeľa, PhD., prof. RNDr. Viliam Foltán, CSc., MUDr. Adriana Ilavská, PharmDr. Tomáš Tesař, PhD.
(6/2008, Pharmacoeconomics ) - Správne poskytovanie zdravotnej starostlivosti v kontexte úhrady liekov zo zdravotného poistenia
JUDr. Katarína Fedorová, PhD., Doc. JUDr. MUDr. Peter Kováč, PhD. et PhD.
(3/2018, Paragraph )
- Evaluation of quality of life for selected neurological diseases
doc. MUDr. Eva Vaňásková, Ph.D., MUDr. Michal Bednář
(3/2013, Main topic ) - Radiotherapy in brain metastases treatment
prof. MUDr. Pavel Šlampa, CSc., doc. MUDr. Radim Jančálek, Ph.D., MUDr. Ludmila Hynková
(5/2016, Main topic )
- PHARMACOECONOMICAL EVALUATION OF ONCOLOGY DRUGS – DIFFICULTIES AND POSSIBLE SOLUTIONS
doc. MUDr. Ján Bielik, CSc., PharmDr. Dominikk Tomek, MPH
(1/2008, Review articles ) - PHARMACOECONOMIC EVALUATION OF DOCETAXEL IN INDUCTION CHEMOTHERAPY OF LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
PharmDr. Dominik Tomek, MPH, MUDr. Milan jamárik
(1/2008, Review articles ) - Cancer drug consumption 2012-2015
Ing. Tomáš Mesároš, MBA, JUDr. Ing. Štefan Mesároš, PhD.
(2/2017, Main topic ) - Criteria of the oncology drugs categorisation process on use of the principle „the value for money“ from the point of view of expected benefits
MVDr., Mgr. Peter Mrva, MPH
(2/2017, Main topic ) - Quantification of the impact of cost-effectiveness threshold on cancer drugs reimbursement in Slovakia
RNDr. Mária Pšenková, MPH, Mgr. Marek Psota, PhD., Ing. Martin Suchanský, doc. RNDr. Martina Ondrušová, PhD., MPH
(2/2017, Main topic ) - Patient´s potential in evaluation of oncologic treatment benefit in the context of quality of life in patients with breast cancer
Doc. MUDr. Ján Bielik, CSc., PhDr. Iveta Matišáková, PHD., Mgr. Renáta Kormancová, MUDr. Branislav Bystrický, RNDr. Vladimír Meluš, PhD., MPH
(2/2017, Main topic ) - Cancer Drugs Fund – starting point or final solution to pay for innovative oncology treatment?
MUDr. Pavol Adamkov, Ing. Petra Szilágyiová, Mgr. Tomáš Pastorek
(1/2014, Main topic ) - Pharmacoeconomics and ethics in oncology: ethical dilemmas and possible solutions
Prof. MUDr. Jozef Glasa, CSc., PhD., MUDr. Helena Glasová, PhD.
(1/2014, Main topic ) - Schôdza Výboru slovenskej onkologickej spoločnosti, Košice, 27. 11. 2013
(1/2014, Information & comments ) - Správa zo 17. celoštátnej pracovnej konferencie SEKCAMA konanej v dňoch 17. a 18. mája 2012
doc. MUDr. Vladimír Bella, PhD.
(3/2012, Events ) - Impact of pricing regulations on access to innovative therapies
Tím Asociácie inovatívneho farmaceutického priemyslu Slovakia, Bratislava
(1/2020, Main topic ) - The aim of QALY in the assessment of cost – effectiveness in oncologic treatment
doc. MUDr. Ján Bielik, CSc., MUDr. Elena Marušáková, MBA
(1/2020, Main topic )
- Trends in hormonal contraception
MUDr. Michael Fanta, Ph.D.
(3/2011, Current pharmacotherapy )